Freedom Capital upgraded Alnylam (ALNY) to Buy from Hold with a price target of $410, down from $470. The company’s Amvuttra continues to post “exceptional” revenue growth both in the U.S. and internationally, the analyst tells investors in a research note. The firm sees the drug’s patient momentum remaining strong in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/13/2026, According to Top Analysts
- Alnylam price target lowered to $360 from $408 at Morgan Stanley
- Alnylam price target lowered to $451 from $491 at Bernstein
- Alnylam price target lowered to $425 from $475 at Chardan
- Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions